Cargando…
Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients
Amikacin pharmacokinetic data in Kuwaiti (Arab) intensive care unit (ICU) patients are lacking. Fairly sparse serum amikacin peak and trough concentrations data were obtained from adult Kuwaiti ICU patients. The data were analysed using a nonparametric adaptive grid (NPAG) maximum likelihood algorit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/ https://www.ncbi.nlm.nih.gov/pubmed/23484093 http://dx.doi.org/10.1155/2013/202818 |
_version_ | 1782260378291404800 |
---|---|
author | Matar, Kamal M. Al-lanqawi, Yousef Abdul-Malek, Kefaya Jelliffe, Roger |
author_facet | Matar, Kamal M. Al-lanqawi, Yousef Abdul-Malek, Kefaya Jelliffe, Roger |
author_sort | Matar, Kamal M. |
collection | PubMed |
description | Amikacin pharmacokinetic data in Kuwaiti (Arab) intensive care unit (ICU) patients are lacking. Fairly sparse serum amikacin peak and trough concentrations data were obtained from adult Kuwaiti ICU patients. The data were analysed using a nonparametric adaptive grid (NPAG) maximum likelihood algorithm. The estimations of the developed model were assessed using mean error (ME) as a measure of bias and mean squared error (MSE) as a measure of precision. A total of 331 serum amikacin concentrations were obtained from 56 patients. The mean (±SD) model parameter values found were V (c) = 0.2302 ± 0.0866 L/kg, k (slope) = 0.004045 ± 0.00705 min per unit of creatinine clearance, k (12) = 2.2121 ± 5.506 h(−1), and k (21) = 1.431 ± 2.796 h(−1). The serum concentration data were estimated with little bias (ME = −0.88) and good precision (MSE = 13.08). The present study suggests that amikacin pharmacokinetics in adult Kuwaiti ICU patients are generally rather similar to those found in other patients. This population model would provide useful guidance in developing initial amikacin dosage regimens for such patients, especially using multiple model (MM) dosage design, followed by appropriate Bayesian adaptive control, to optimize amikacin dosage regimens for each individual patient. |
format | Online Article Text |
id | pubmed-3581152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35811522013-03-12 Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients Matar, Kamal M. Al-lanqawi, Yousef Abdul-Malek, Kefaya Jelliffe, Roger Biomed Res Int Research Article Amikacin pharmacokinetic data in Kuwaiti (Arab) intensive care unit (ICU) patients are lacking. Fairly sparse serum amikacin peak and trough concentrations data were obtained from adult Kuwaiti ICU patients. The data were analysed using a nonparametric adaptive grid (NPAG) maximum likelihood algorithm. The estimations of the developed model were assessed using mean error (ME) as a measure of bias and mean squared error (MSE) as a measure of precision. A total of 331 serum amikacin concentrations were obtained from 56 patients. The mean (±SD) model parameter values found were V (c) = 0.2302 ± 0.0866 L/kg, k (slope) = 0.004045 ± 0.00705 min per unit of creatinine clearance, k (12) = 2.2121 ± 5.506 h(−1), and k (21) = 1.431 ± 2.796 h(−1). The serum concentration data were estimated with little bias (ME = −0.88) and good precision (MSE = 13.08). The present study suggests that amikacin pharmacokinetics in adult Kuwaiti ICU patients are generally rather similar to those found in other patients. This population model would provide useful guidance in developing initial amikacin dosage regimens for such patients, especially using multiple model (MM) dosage design, followed by appropriate Bayesian adaptive control, to optimize amikacin dosage regimens for each individual patient. Hindawi Publishing Corporation 2013 2013-01-30 /pmc/articles/PMC3581152/ /pubmed/23484093 http://dx.doi.org/10.1155/2013/202818 Text en Copyright © 2013 Kamal M. Matar et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Matar, Kamal M. Al-lanqawi, Yousef Abdul-Malek, Kefaya Jelliffe, Roger Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients |
title | Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients |
title_full | Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients |
title_fullStr | Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients |
title_full_unstemmed | Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients |
title_short | Amikacin Population Pharmacokinetics in Critically Ill Kuwaiti Patients |
title_sort | amikacin population pharmacokinetics in critically ill kuwaiti patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/ https://www.ncbi.nlm.nih.gov/pubmed/23484093 http://dx.doi.org/10.1155/2013/202818 |
work_keys_str_mv | AT matarkamalm amikacinpopulationpharmacokineticsincriticallyillkuwaitipatients AT allanqawiyousef amikacinpopulationpharmacokineticsincriticallyillkuwaitipatients AT abdulmalekkefaya amikacinpopulationpharmacokineticsincriticallyillkuwaitipatients AT jellifferoger amikacinpopulationpharmacokineticsincriticallyillkuwaitipatients |